The purpose of this study is to evaluate the effect of dapagliflozin on the incidence of cancer therapeutics-related cardiac dysfunction in patients with breast cancer receiving anthracycline treatment.
Age > 18 years and < 80 years.
Diagnosis of invasive breast cancer [stage I-III] and planned anthracycline treatment within 60 days.
Signed Informed Consent to participate in the study.
Urinary tract infection with the need for treatment with an antibiotic 48 hours before the scheduled start of anthracycline treatment.
Recognised heart failure or symptoms which, in the opinion of the investigator may be a symptom of undiagnosed heart failure.
Left ventricular ejection fraction < 50% at the time of the screening.
Severe valvular heart disease.